Cancer NetworkOriginal article
<![CDATA[Teclistamab/Talquetamab Hits Record Low Hazard Ratio in Multiple Myeloma]]>
Data ReadoutpositiveTeclistamabTalquetamabPositive
AI Analysis
Summary
Teclistamab-talquetamab combination demonstrated a record 89% reduction in progression risk in the MonumenTAL-6 trial for multiple myeloma. This represents a positive efficacy signal for the dual bispecific antibody approach.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Teclistamab-talquetamab combination reduced progression risk by 89% in MonumenTAL-6 trial
Importance:7/10
Sentiment:
0.85
multiple myelomabispecific antibodycombination therapyhazard ratioMonumenTAL-6
Read the original article
Published by Cancer Network on August 2, 2026 4:00 PM